Genmab
Clinical Trials
240
Trial Phases
4 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (185 trials with phase data)• Click on a phase to view related trials
Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)
- Conditions
- Cutaneous MelanomaRelapsed/Refractory, Locally Advanced Unresectable Melanoma (Stage IIIB, IIIC, or IIID)Metastatic Cutaneous Melanoma (Stage IV)
- Interventions
- First Posted Date
- 2025-05-22
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Genmab
- Target Recruit Count
- 90
- Registration Number
- NCT06984328
- Locations
- 🇵🇷
Pan American Center for Oncology Trials, LLC, San Juan, Puerto Rico
A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors
- First Posted Date
- 2025-01-13
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- Genmab
- Target Recruit Count
- 3
- Registration Number
- NCT06771921
- Locations
- 🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain
🇪🇸NEXT Oncology Madrid, Madrid, Spain
🇩🇰Righshospitalet (Copenhagen University Hospital), Copenhagen, Denmark
A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Genmab
- Target Recruit Count
- 260
- Registration Number
- NCT06685068
- Locations
- 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸START San Antonio, San Antonio, Texas, United States
🇺🇸START Mountain Region, West Valley City, Utah, United States
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
- Conditions
- PD-L1-positive Metastatic NSCLC
- Interventions
- First Posted Date
- 2024-10-10
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Genmab
- Target Recruit Count
- 702
- Registration Number
- NCT06635824
- Locations
- 🇺🇸
Usc Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Kaiser Permanente Vallejo Medical Center, Vallejo, California, United States
🇺🇸Ocala Oncology Center P.L., Ocala, Florida, United States
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Platinum Resistant Ovarian Cancer
- Conditions
- Platinum-resistant Ovarian Cancer
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-05-26
- Lead Sponsor
- Genmab A/S
- Target Recruit Count
- 171
- Registration Number
- 2024-514822-21-00
- Locations
- 🇦🇹
Ordensklinikum Linz GmbH, Linz, Austria
🇦🇹Medizinische Universitaet Innsbruck, Innsbruck, Austria
🇦🇹Klinik Hietzing, Vienna, Austria
- Prev
- 1
- 2
- 3
- 4
- 5
- 11
- Next
News
Commit Biologics Forms Scientific Advisory Board to Advance Complement-Based Cancer and Autoimmune Therapies
Commit Biologics has established a Scientific Advisory Board co-chaired by antibody expert Janine Schuurman and CEO Mikkel Wandahl Pedersen to guide development of its BiCE™ complement activation platform.
Epcoritamab Demonstrates Durable 3-Year Remissions in Relapsed/Refractory Large B-Cell Lymphoma
Epcoritamab-bysp achieved durable complete responses in patients with relapsed/refractory large B-cell lymphoma, with 96% of complete responders at 2 years maintaining remission at 3 years.
World ADC San Diego Conference Highlights Growing Industry Focus on Antibody-Drug Conjugates
The 15th World ADC San Diego conference (November 4-7, 2024) represents the industry's largest and most comprehensive ADC-focused forum, featuring 120+ speakers across six development tracks.
Genmab to Present Extensive Epcoritamab Clinical Data at 2025 European Hematology Association Congress
Genmab will showcase 14 abstracts evaluating epcoritamab, their subcutaneously administered T-cell engaging bispecific antibody, across multiple lymphoma settings at the 2025 EHA Congress in Milan.
Lundbeck Presents Phase II Data for Amlenetug in Multiple System Atrophy at International Congress
Lundbeck presented results from the AMULET phase II trial investigating amlenetug, a monoclonal antibody targeting α-synuclein, as a potential treatment for multiple system atrophy (MSA).
Genmab Plans FDA Submission for Epcoritamab Combination Therapy in Relapsed Follicular Lymphoma
Genmab and AbbVie will submit a supplemental Biologics License Application (sBLA) to the FDA for epcoritamab in combination with rituximab and lenalidomide for relapsed/refractory follicular lymphoma patients.
Genmab Reports Strong Q1 2025 DARZALEX Sales of $3.24 Billion, Demonstrating Continued Market Dominance
DARZALEX (daratumumab) generated $3.24 billion in global net sales during Q1 2025, with $1.83 billion from U.S. markets and $1.41 billion internationally.
AbbVie Files Trade Secret Lawsuit Against Genmab Over ADC Technology in Cancer Drug Development
AbbVie has filed a lawsuit against Genmab and ProfoundBio alleging misappropriation of trade secrets related to disaccharide technology in antibody-drug conjugates, which Genmab categorically refutes.
Elahere Demonstrates Significant Survival Benefit in Phase III MIRASOL Trial for Platinum-Resistant Ovarian Cancer
AbbVie's final analysis of the phase III MIRASOL trial confirms Elahere (mirvetuximab soravtansine) provides superior efficacy compared to chemotherapy in folate receptor alpha-positive platinum-resistant ovarian cancer patients.
DARZALEX Dominates Multiple Myeloma Market with $11.6 Billion in Global Sales
• DARZALEX (daratumumab), Janssen's CD38-targeting monoclonal antibody, has transformed multiple myeloma treatment across all lines of therapy, generating $11.6 billion in worldwide sales in 2024. • The drug's success stems from its versatility in combination regimens, expanded approvals for both newly diagnosed and relapsed/refractory patients, and the introduction of DARZALEX FASPRO, a convenient subcutaneous formulation. • Despite growing competition from emerging therapies like Sanofi's SARCLISA and novel BCMA-targeting agents, DARZALEX maintains market leadership through first-mover advantage and robust clinical efficacy data.